Effect of Velphoro on Serum Phosphate and Albumin in Peritoneal Dialysis Patients

Phase 4 Completed 17 enrolled University of Colorado, Denver

NaSingle-groupOpen-labelTreatment

Summary

Prospective pilot study to determine if changing the phosphate binder to sucroferric oxyhydroxide for for 6 months improves disordered mineral metabolism and nutrition status in peritoneal dialysis patients.

Timeline

Start: 2020-02-01
Primary completion: 2021-07-31
Completion: 2021-07-31

Outcome

Mixed primary results

paper Participants' serum phosphate significantly decreased with fewer phosphate binder pills/day after switching to SO. PMID 35810296 ↗

paper There was no change in serum albumin, appetite, or dietary intake. PMID 35810296 ↗

paper However, participants had significant improvements in phosphorus-attuned albumin. PMID 35810296 ↗

Publications

Perez L, You Z, Teitelbaum I, Andrews ES, Reddin R, Ramirez-Renteria L, Wilson G, Kendrick J. A 6-Month clinical practice pilot study of sucroferric oxyhydroxide on nutritional status in patients on peritoneal dialysis. BMC Nephrol. 2022 Jul 9;23(1):245. doi: 10.1186/s12882-022-02878-5.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	PA21	Unknown	500 mg	—